Yabao Pharmaceutical Group Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include Chinese and Western medicine preparations, patches, active pharmaceutical ingredients and pharmaceutical packaging materials. The Company's products mainly involve pediatrics, adult medicines and health products. The Company sells its products under the brands of Yabao, Dinggui, Yabao Lishu and Yabao Weiyuan. The Company mainly operates its businesses in the domestic and overseas markets.

Employees

3,415

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
27/26/27	CN¥7.200	+0.42%	2,19,76,120
26/26/26	CN¥7.170	+2.43%	3,57,42,461
25/26/25	CN¥7.000	+3.24%	2,44,84,927
24/26/24	CN¥6.780	-1.31%	1,95,98,659
21/26/21	CN¥6.870	-3.92%	3,06,07,954

End-of-day quote Shanghai S.E.

More quotes

End-of-day quote Shanghai S.E. 25/08/2026			5-day change	1st Jan Change
7.000 ^CNY	+3.24%		-1.27%	+7.86%

01/08	Shanxi Yabao Pharmaceutical Logistics Distribution Co., Ltd. announced that it expects to receive CNY 50 million in funding from Yabao Pharmaceutical Group Co., Ltd	CI
01/08	Beijing Yabao Biopharmaceutical Co., Ltd. announced that it has received CNY 100 million in funding from Yabao Pharmaceutical Group Co., Ltd	CI

Market Cap	498.24Cr 74Cr 64Cr 60Cr 55Cr 102.76Cr 7.08TCr 103.06Cr 705.45Cr 275.77Cr 3.57TCr 278.32Cr 272.31Cr 12TCr	P/E 2024	18.1x	P/E 2025	14.2x
Enterprise Value	419.8Cr 62Cr 54Cr 50Cr 46Cr 87Cr 5.97TCr 87Cr 594.39Cr 232.36Cr 3.01TCr 234.5Cr 229.44Cr 9.95TCr	EV / Sales 2024	1.45x	EV / Sales 2025	1.65x
Free-Float	79.74%	Yield 2024	4.93%	Yield 2025	5.39%

01/08	Shanxi Yabao Pharmaceutical Logistics Distribution Co., Ltd. announced that it expects to receive CNY 50 million in funding from Yabao Pharmaceutical Group Co., Ltd	CI
01/08	Beijing Yabao Biopharmaceutical Co., Ltd. announced that it has received CNY 100 million in funding from Yabao Pharmaceutical Group Co., Ltd	CI
31/07	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI
31/07	Yabao Pharmaceutical Group Co., Ltd announces an Equity Buyback for CNY 200 million worth of its shares.	CI
31/07	Yabao Pharmaceutical Group Co., Ltd authorizes a Buyback Plan.	CI
25/05	Yabao Pharmaceutical Subsidiary Secures Chinese Regulatory Approval for High Cholesterol Tablets	MT
24/04	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
24/04	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
22/12	Shanxi Tongxiang Times Technology Co., Ltd. completed the acquisition ofan additional 62% stake in Yabao Pharmaceutical Taiyuan Pharmaceutical Co., Ltd. from Yabao Pharmaceutical Group Co., Ltd.	CI
18/12	Yabao Pharma Gets Clinical Trial Nod for Pulmonary Arterial Hypertension Drug	MT
17/11	Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 17, 2025.	CI
14/11	Yabao Pharmaceutical Group Co., Ltd's Equity Buyback announced on May 17, 2025, has closed with 8,000,000 shares, representing 1.14% for CNY 52.15 million.	CI
13/11	Yabao Pharmaceutical Obtains Registration for Children's Nutrition Product	MT

30/16/30	Yabao Pharmaceutical : Pharmaceuticals and LFB Biomedicaments Enter Into Strategic Partnership to Deliver VIALEBEX® (LFB’s Human Albumin) in China	BU
20/16/20	Yabao Pharmaceutical : Pharmaceuticals and Salus Pharma Announce Strategic Partnership for Generic Drugs	BU
12/16/12	Yabao Pharmaceuticals : and Sciecure Pharma Announce Strategic Partnership to Co-develop, Manufacture and Commercialize Generics for U.S. and China	BU
20/15/20	Yabao Pharmaceuticals : Enters Second Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment	BU
15/15/15	Yabao Pharmaceuticals : and Primary Peptides Announce Exclusive China Partnership	BU

Yabao Pharmaceutical Group Co., Ltd Share Price

Stocks

600351

CNE000001CM5

Pharmaceuticals

Valuation : Yabao Pharmaceutical Group Co., Ltd

Chart: Yabao Pharmaceutical Group Co., Ltd

Latest news : Yabao Pharmaceutical Group Co., Ltd

Press Releases : Yabao Pharmaceutical Group Co., Ltd

News in other languages : Yabao Pharmaceutical Group Co., Ltd

Quotes and Performance

Price Extremes

Managers and Directors : Yabao Pharmaceutical Group Co., Ltd

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 day	+3.24%
1 week	-1.27%
Current month	+8.19%
1 month	+9.20%
3 months	+9.55%
6 months	+4.63%
Current year	+7.86%

1 week	6.72	7.22
1 month	6.33	7.45
Current year	5.6	7.45
1 year	5.6	7.45
3 years	4.94	9
5 years	4.94	11.9
10 years	4.5	11.9

Manager	Title	Age	Since
Wei Ren CEO	Chief Executive Officer	42	23/04/2019
Zhe Feng Zuo DFI	Director of Finance/CFO	54	17/05/2017
Peng Bo Ren PRN	Corporate Officer/Principal	53	11/03/2007

Director	Title	Age	Since
Wu Xian Ren CHM	Chairman	66	26/05/2005
Min Xuan Cui BRD	Director/Board Member	66	16/06/2020
Peng Bo Ren BRD	Director/Board Member	53	15/05/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
YABAO PHARMACEUTICAL GROUP CO., LTD	+3.24%	-1.27%	-4.24%	-6.67%	74Cr
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.73%	+0.70%	+19.56%	+71.29%	4.78TCr
OTSUKA HOLDINGS CO., LTD.	-0.37%	+1.04%	+54.31%	+121.86%	4.03TCr
CIPLA LIMITED	+1.23%	-0.14%	-10.12%	+15.55%	1.19TCr
ZYDUS LIFESCIENCES LIMITED	+3.41%	+7.67%	+20.38%	+87.48%	1.2TCr
KRKA, D. D.	+0.19%	0.00%	+30.98%	+150.00%	924.22Cr
GEDEON RICHTER	+0.45%	+3.73%	+25.09%	+46.01%	782.51Cr
ONO PHARMACEUTICAL CO., LTD.	-1.41%	-0.16%	+52.26%	-11.99%	734.47Cr
GLENMARK PHARMACEUTICALS LIMITED	+0.89%	+9.50%	+26.11%	+220.67%	721.43Cr
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+0.95%	-8.22%	-39.88%	+16.67%	527.97Cr
Average	+0.93%	+1.22%	+17.45%	+71.09%	1.5TCr
Weighted average by Cap.	+0.56%	+1.06%	+27.33%	+86.13%

	2024	2025
Net sales	268.6Cr 40Cr 34Cr 32Cr 29Cr 55Cr 3.82TCr 56Cr 380.31Cr 148.67Cr 1.92TCr 150.04Cr 146.8Cr 6.37TCr	224.01Cr 33Cr 29Cr 27Cr 25Cr 46Cr 3.18TCr 46Cr 317.17Cr 123.98Cr 1.6TCr 125.13Cr 122.43Cr 5.31TCr
Net income	24Cr 3.61Cr 3.1Cr 2.9Cr 2.66Cr 5.01Cr 344.86Cr 5.02Cr 34Cr 13Cr 173.81Cr 14Cr 13Cr 575.23Cr	32Cr 4.76Cr 4.09Cr 3.83Cr 3.5Cr 6.6Cr 454.74Cr 6.62Cr 45Cr 18Cr 229.18Cr 18Cr 17Cr 758.51Cr
Net Debt	-48Cr -7.18Cr -6.17Cr -5.77Cr -5.29Cr -9.96Cr -686.19Cr -9.99Cr -68Cr -27Cr -345.83Cr -27Cr -26Cr -1.14TCr	-78Cr -12Cr -10Cr -9.38Cr -8.59Cr -16Cr -1.11TCr -16Cr -111.06Cr -43Cr -561.73Cr -44Cr -43Cr -1.86TCr